D-amino acid oxidase (DAO) is a flavoenzyme that metabolizes certain D-amino acids, notably the endogenous N-methyl D-aspartate receptor (NMDAR) co-agonist, D-serine. As such, it has the potential to modulate the function of NMDAR and to contribute to the widely hypothesized involvement of NMDAR signalling in schizophrenia. Three lines of evidence now provide support for this possibility: DAO shows genetic associations with the disorder in several, although not all, studies; the expression and activity of DAO are increased in schizophrenia; and DAO inactivation in rodents produces behavioural and biochemical effects, suggestive of potential therapeutic benefits. However, several key issues remain unclear. These include the regional, cellular and subcellular localization of DAO, the physiological importance of DAO and its substrates other than D-serine, as well as the causes and consequences of elevated DAO in schizophrenia. Herein, we critically review the neurobiology of DAO, its involvement in schizophrenia, and the therapeutic value of DAO inhibition. This review also highlights issues that have a broader relevance beyond DAO itself: how should we weigh up convergent and cumulatively impressive, but individually inconclusive, pieces of evidence regarding the role that a given gene may have in the aetiology, pathophysiology and pharmacotherapy of schizophrenia? Molecular Psychiatry (2010) 15, 122-137;
Introduction
The enzyme D-amino acid oxidase (DAO) was discovered in the porcine kidney almost 75 years ago, 1 and has since been extensively studied as a model flavin-dependent oxidase. DAO is now of interest in psychiatry (Table 1) 1-12 because its major substrate in the brain is D-serine, a co-agonist of the N-methyl D-aspartate type of ionotropic glutamate receptor (NMDAR); therefore, DAO has the capability to regulate the function of NMDAR through D-serine breakdown and might contribute to NMDAR hypofunction in schizophrenia, or be relevant to its remediation. Herein, we review the biology of DAO in the brain, the evidence for its involvement in schizophrenia and its therapeutic potential in the disorder.
The neurobiology of DAO
The DAO gene and its products The human DAO gene is located at chromosome 12q24 and comprises 11 exons (Figure 1 ). The fulllength transcript is 1595 bp 4, 13 and shows 78 and 77% nucleotide homology with mouse 14 and rat 15 DAO, respectively. The human DAO transcript encodes a B39-kDa protein of 347 amino acids, 4 and a single major band is detected on western blots. [16] [17] [18] [19] [20] Although only a single DAO mRNA or protein has been unequivocally shown, there may be isoforms of DAO. The possibility of the presence of additional DAO transcripts is suggested by the presence of transcription initiation sequences in the first intron, 13 which may be relevant to the discovery of a human brain DAO mRNA variant with a 5 0 -untranslated region deletion. 21 This is of interest, given that the 5 0 -untranslated region of the rabbit kidney DAO acts as a translational repressor. 22 Variants may also occur within the 3 0 -untranslated region through multiple polyadenylation signals. 15, 23 A final transcript variant, lacking exon 9, has been identified from mouse cDNA libraries. 24 At the protein level, a DAO immunoreactive band, approximately 1-1.5 kDa smaller than the full-length DAO, is detectable in the kidney, 25 and there are two active isozymes reported in the human kidney. 26 Sacchi et al., 20 immunoprecipitated a B34-kDa DAO band in the brain, but noted that the extra band(s) could reflect proteolysis, as described previously for DAO, 27 or cross-reactivity. Overall, there remains no conclusive evidence for functional isoforms of human DAO, but it is attractive to postulate their existence as an explanation for various unexplained observations, suggestive of DAO heterogeneity discussed below.
Actions of DAO in the brain D-amino acid oxidase oxidizes D-amino acids through concomitant reduction of its prosthetic group, flavin adenine dinucleotide, producing the corresponding imino acid; this is then hydrolyzed to yield ammonia and the corresponding a-keto acid. Hydrogen peroxide is produced during flavin reoxidation (Figure 2 ; reviewed in Pilone 28 and Pollegioni et al.
29
). Flavin adenine dinucleotide binding is notably weaker in Increased DAO activity in schizophrenia 11, 12 Abbreviations: DAO, D-amino acid oxidase; LTP, long-term potentiation; PCP, phencyclidine. * * * * * Figure 1 The D-amino acid oxidase (DAO) gene and transcript. The DAO gene on 12q24 comprises 11 known exons (numbered). Exon 1 plus 9 base pairs of exon 2 encode the 5 0 -untranslated region (shaded grey) of the DAO transcript, exons 2-11 encode the open-reading frame (start codon ATG, stop codon TGA), and exon 11 encodes the 3 0 -untranslated region (shaded grey). The transcriptional start site is in exon 1 and the 5 0 -flanking sequence contains GC box, cAMP-responsive element and sterol-dependent repressor sequences (long grey dashed arrow). Intron 1 contains additional regulatory sequences, three TATA boxes and a transcription-enhancing CAAT box (short grey dashed arrow). The position of several single-nucleotide polymorphisms (SNPs) associated with schizophrenia in the original study 8 are shown: rs211902 (MDAAO4); rs3918346 (MDAAO5); rs3741775 (MDAAO6) and rs3918347 (MDAAO7). In addition, rs4623951 (MDAAO11) was significantly associated with schizophrenia in two meta-analyses, 175, 179 and rs3825251 and rs4964770 are part of a haplotype associated with schizophrenia in a recent Japanese study. 168 rs4964770 is located in the region downstream of DAO. Finally, rs2070587 is a tag SNP studied for a potential effect on DAO expression and activity.
human DAO than in DAO from other species examined, providing a potential means to regulate DAO activity in humans as flavin adenine dinucleotide-unbound DAO, although it binds the substrate, is catalytically inactive. 30 DAO is characteristic of flavin-dependent oxidases by displaying stereospecificty to D-amino acids. It selectively oxidizes those with small, neutral side chains, notably D-serine, D-alanine, D-proline and D-leucine, for which human DAO shows affinities (Km) of approximately 1-10 mM. 31, 32 D-amino acid oxidase enzyme activity was discovered in the mammalian brain more than 40 years ago. 3, 33 However, its significance remained enigmatic until the discovery of D-amino acids in brain tissue, including the DAO substrates D-alanine, D-serine, D-leucine and D-proline, of which D-serine is by far the most abundant (Table 2) . 18, A further, key piece of the jigsaw was provided by the discovery of an enzyme enriched in the brain that synthesizes D-serine from L-serine, known as serine racemase (SRR). 55, 56 Although some brain D-serine could arise from the periphery and diet, 39, 57 it is likely that most brain D-serine is largely the result of local synthesis from L-serine. 58 A peripheral origin may well be greater for, if not the sole source of, the other D-amino acids mentioned, for which synthetic enzymes in the brain have not been demonstrated. Consistent with this, D-alanine levels increase in the brain after oral administration. 59 D-amino acid oxidase has a modest affinity for its substrates in the context of their low concentrations in the brain (Table 2 ). This has led to some doubt regarding the physiological relevance of the enzyme in vivo, 31, 60 but evidence for the functionality of central DAO comes from two main sources. First, the ddY/DAO-mouse, which lacks active DAO due to a point mutation (Gly181Arg). 5, 61 In these mice, levels of D-serine and other DAO substrates are increased several-fold in most brain areas (see Table 2 , righthand column), in keeping with a major role of DAO in their metabolism. Second, oral or systemic administration of DAO inhibitors to normal rodents can increase central D-serine levels. 10, 62 However, the ddY/DAO-data also show some interesting complexities. D-serine and D-proline are either unchanged or are only minimally increased in the cerebral cortex in contrast to their marked increases in the cerebellum, consistent with the view that DAO has at most a minor role in the forebrain (see below). On the other hand, Dalanine and D-leucine levels are elevated in the cerebral cortex of ddY/DAO-mice by a similar magnitude to that in the cerebellum. This pattern of results in the ddY/DAO-mouse illustrates the fact that there is more to the metabolism of brain D-amino acids than just locally acting DAO-potentially including selective D-amino acid uptake into the brain, 58, 63, 64 other enzymes and transporters (which may differ in their selectivity for different D-amino acids, and in their distribution within the brain), and a role of peripheral as well as central actions of DAO.
39,50
The role of DAO in NMDAR modulation The NMDAR requires, in addition to glutamate, binding of a co-agonist at the 'strychnine-insensitive glycine modulatory site' in order to open. Several studies have indicated that, besides glycine, D-serine binds at this site and facilitates NMDAR function. [65] [66] [67] Moreover, seminal studies, which showed enrichment of D-serine to forebrain astrocytes that concentrated around NMDAR 2A/B subunits, 68, 69 led to the proposal that D-serine is the endogenous NMDAR coagonist, at least in the forebrain. [70] [71] [72] [73] [74] [75] [76] [77] [78] Numerous studies have verified that endogenous and exogenous D-serine potentiates NMDAR function. [79] [80] [81] [82] [83] [84] [85] [86] [87] The evidence that D-serine is the main NMDAR co-agonist in the forebrain, together with its greater abundance compared with other D-amino acids, explains the predominance of studies focusing on the roles and regulation of D-serine. In passing, it is worth noting that D-alanine can also act as an NMDAR coagonist 67, 88 and that human DAO has a higher affinity for D-alanine than for D-serine (1.3 vs. 7.5 mM). 31 However, the low concentration of D-alanine (B10% that of D-serine; Table 2 ), and the absence of a known synthetic enzyme, cast doubt on whether it is a physiological NMDAR co-agonist.
In light of these considerations, it is possible that DAO could influence physiological NMDAR function through the modulation of D-serine availability in the synapse. Some evidence exists to support this notion. First, exogenous DAO reduces NMDAR function in vivo and in vitro. 70, [89] [90] [91] [92] [93] [94] Second, ddY/DAO-mice show increased cerebellar NMDAR function 17 and enhanced hippocampal NMDAR-dependent longterm potentiation. 9 Third, systemically administered DAO inhibitors produce effects consistent with enhanced NMDAR function (see below). It must be noted that findings in both the latter types of study could reflect the lack or inhibition of peripheral DAO (leading to higher circulating levels of its substrates) rather than that of central DAO. Direct evidence that local actions of endogenous brain DAO are functional is, to our knowledge, limited to a pharmacological study showing that DAO inhibition localized to the ventral tegmental area augments NMDAR-dependent behaviours. 95 Apart from NMDAR modulation, other roles of DAO substrates, and thus of DAO itself, may exist. D-serine antagonizes a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid glutamate receptors, 96 suggesting that D-serine and DAO could be involved in both positive and negative modulatory effects at glutamatergic synapses. D-serine is also an endogenous ligand at the GluRd2 receptor, which is an ionotropic glutamate-like receptor important in cerebellar development and plasticity. 97 D-serine may also modulate glycinergic transmission by antagonizing NR1/NR3A or NR1/NR3B receptors, which are insensitive to glutamate and activated by glycine. 98, 99 D-serine also binds to human platelet 5-HT 3 receptors. 100 D-proline does not act at NMDARs but can activate glycine receptors, 101 whereas D-leucine is a potent regulator of the blood-brain barrier enkephalin 36, 45, 53 Some values are approximate as they were estimated from graphical data. The right-hand column shows the significant fold increases of the D-amino acid in the ddY/DAO À mouse compared with wild-type mice. Variability in results in the rodent brain likely reflects the assay methods used, and the age, gender and strain; in the human brain, peri-mortem factors are also relevant. 41, 51 a With a twofold increase in ddY/DAO þ /À heterozygotes. b With no change in ddY/DAO þ /À heterozygotes. transport system. 102 It is not known whether any of these various additional actions of D-amino acids have any significance with regard to DAO and its involvement in schizophrenia.
Distribution of DAO in the brain and its spatial relationships with its substrates There are several complexities and controversies regarding the localization of DAO in the brain, in terms of region, cell type and subcellular compartment, as well as regarding the relationship between expression and activity.
Regional activity and expression. On the basis of activity assays, DAO has traditionally been viewed as a hindbrain enzyme, 3, 6, 33, 49, 59, 68, 103, 104 although DAO activity has also be detected in the forebrain in some studies, albeit only at a small fraction (B1-5%) of that observed in the cerebellum. 3, 12, 103, 105 Notwithstanding these barely detectable levels of enzyme activity, DAO mRNA is consistently detectable in forebrain regions, both in rodents 21, [106] [107] [108] [109] and in humans. 19, 21 DAO immunoreactivity is also detectable in cortical homogenates, 17, 18, 20 and by immunohistochemistry in the frontal cortex, hippocampus and midbrain. 7, 19, 20 A precedent for these findings exists in the rabbit kidney, where the presence of DAO mRNA and protein contrasts with undetectable DAO activity. 22 In humans, the presence of inactive forms of DAO protein could be related to the weaker flavin adenine dinucleotide binding of human DAO noted earlier. 30 Regardless of the mechanism, the unequivocal expression of DAO, but minimal enzyme activity, raises the possibility that forebrain DAO might have different and as yet unidentified functions to hindbrain DAO. As an aside, the reciprocal issue concerns how D-serine and other DAO substrates are metabolized in the forebrain if DAO is essentially inactive therein. 76 One possibility is that regulation occurs through transport and recycling (between cells and synapses, as well as between the brain and periphery), rather than by local degradation. Alternatively, D-serine may be regulated by the a,b-eliminase or reverse racemase functions of SRR, which convert D-serine to pyruvate and L-serine respectively, although their contributions under physiological conditions remain unclear. 110, 111 A third possibility is that an additional, unidentified D-serine degrading enzyme exists in the forebrain.
Cellular expression. It is also controversial as to which cell types express DAO in the brain. DAO is conventionally described as being a glial enzyme, on the basis of histochemical studies which show cerebellar DAO activity localized in astrocytes and the Bergmann glia. 6, 33, 104 The presence of DAO in these cells is supported by immunohistochemistry in the rat 7 and in humans, 19 as well as by in situ hybridization detection of DAO mRNA. 19 DAO is also present in the glia of the hippocampus and cerebral cortex. 7, 19, 20 There is increasing evidence that DAO is not solely glial. DAO immunoreactivity has been reported in both Golgi and Purkinje cells in the rat, 7 In the hippocampus and cerebral cortex, pyramidal neurons show DAO immunoreactivity 7, 19 and express DAO mRNA. 19 DAO also localizes to neurons in the dopaminergic midbrain nuclei. 7, 19 However, a wellconducted recent study, with a novel antibody, conspicuously failed to demonstrate neuronal DAO immunoreactivity in human cortical or diencephalic tissue. 20 In total, the evidence that DAO is expressed by neurons as well as glia is strong but not compelling. More detailed cellular mRNA studies (with in situ hybridization and single-cell type approaches) as well as the availability and application of more anti-DAO antibodies will help clasify the situation.
The issue of which cell types contain DAO is important with regard to D-serine uptake. A largely glial localization of DAO would seem to contrast with the fact that Asc-1, the primary means of synaptic Dserine transport, 112 is expressed predominantly, if not exclusively, by neurons. [113] [114] [115] Furthermore, a second D-serine transporter, ASCT2, [116] [117] [118] believed to be glial, 119 is now also reported to be localized to neurons. 120 These data suggest that a substantial portion of synaptic D-serine is taken up into the neurons, thus indirectly supporting the possibility that DAO is functional in both the neurons and glia. Subcellular localization. Ultrastructural and biochemical studies have shown that DAO is a peroxisomal enzyme. 7, 104, [121] [122] [123] [124] It is targeted to peroxisomes as a partially folded inactive intermediate, which exposes a C-terminal peroxisomal targeting sequence encoded by the eleventh exon. 23, 125 Transport of an inactive form of DAO is presumably beneficial as the production of hydrogen peroxide by DAO in other cellular compartments may be deleterious; 125 indeed, DAO overexpression in glial cells is cytotoxic through hydrogen peroxide production. 126 However, complicating matters, DAO may also occur in other cell compartments. The C-terminal sequence of DAO is prone to proteolysis 127, 128 and conceivably, if proteolysis occurred outside peroxisomes, DAO might not be targeted to the organelle and may function elsewhere. Consistent with this, cleavage of the C-terminal 2 kDa of porcine DAO yields a fully active DAO protein, 129 and yeast mutants that express DAO lacking the peroxisomal targeting sequence have active cytosolic DAO. 130 Notably, a detailed co-localization study found that a large proportion of DAO in human astrocytes does not overlap with peroxisomal markers. 20 This nonperoxisomal form of DAO was suggested to relate to an electrophoretically more mobile form of DAOpossibly related to proteolytic cleavage events-and might relate to earlier data suggestive of DAO in other cellular compartments, including non-peroxisomal cytoplasmic granules 131 and the plasma membrane. 132 The subcellular distribution of DAO is relevant to the question of how it 'sees' its substrates. For DAO located outside the peroxisome, accessibility of DAO to its substrates would likely not be an issue. However, in its classical peroxisomal location, presumably a transport mechanism for the D-amino acids from the cytosol into the peroxisome is required. Possible candidates include dsr-1, a gene that is expressed in the brain, is upregulated by D-serine and is predicted to encode a membrane-spanning transport protein, 133 and dsm-1, which is expressed by neurons, affects D-serine transport and shows a punctuate, cytoplasmic localization when expressed in COS-7 cells. 134 In summary, the view that DAO is a peroxisomal, glial, hindbrain enzyme is too simplistic: DAO is likely neuronal and glial, may be localized outside and within peroxisomes and may be present in the forebrain even if its significance therein remains ambiguous (Figure 3) . The relative importance and functionality of DAO in these various locations is unclear, and it is unknown whether there are associated differences in the activity or regulation of the enzyme. Nevertheless, the more nuanced situation that is shown by recent data (Figure 3b ) provides both a challenge and an opportunity to better understand the physiological and pathophysiological role of DAO. Parenthetically, comparable unforeseen complexities regarding SRR have recently emerged. Initially viewed as being glial and cytosolic, 56 SRR is now believed to be partially, if not largely, neuronal 135, 136 and to be prominently associated with the plasma membrane. 137, 138 Moreover, redistribution between cytosol and membrane has a crucial role in the determination of SRR activity and its regulation by glutamate signalling. 137, 138 It remains to be shown whether these findings impact on DAO, or are indicative of a spatially co-ordinated process of Role of DAO in schizophrenia L Verrall et al D-serine synthesis and degradation, but they do illustrate that there could be many complexities in the expression, activity and regulation of DAO that await discovery.
The role of DAO in schizophrenia
Glutamate dysfunction in schizophrenia was first suggested from observations that the NMDAR antagonist, phencyclidine, produces a schizophrenia-like phenotype. 139 Subsequently, converging pharmacological, genetic, neuropathological and other data have led to the widely supported NMDAR hypofunction model of schizophrenia. [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] A more specific variant of this hypothesis envisages that a deficiency of D-serine signalling contributes to NMDAR hypofunction, a view supported by the following lines of evidence: (1) Decreased D-serine levels have been reported in schizophrenia. Hashimoto et al. 150 demonstrated significant reductions in serum D-serine, and subsequently lower D-serine as a proportion of total (D þ L)-serine in cerebrospinal fluid, 151 a finding replicated by the same group in serum 152 and by an independent group in cerebrospinal fluid. 18 (2) Therapeutic effects have been observed in some clinical trials with D-serine, the partial agonist Dcycloserine, and with D-alanine, when added to antipsychotic medication; [153] [154] [155] [156] [157] a meta-analysis concluded that D-serine is beneficial for negative symptoms, with a trend effect on cognitive symptoms. 158 (3) In animal models, D-serine produces behavioural and neurochemical alterations consistent with these clinical effects. 88, [159] [160] [161] [162] [163] These factors suggest that DAO, through its role in the metabolism of D-serine-and perhaps D-alaninemay be a potential contributor to, and treatment target for, the proposed NMDAR involvement in schizophrenia. We now review evidence that DAO may be a schizophrenia susceptibility gene, that DAO expression and activity are increased in the disorder and that DAO inhibition may be a novel therapeutic approach.
Genetic association of DAO with schizophrenia
The landmark study by Chumakov et al., 8 identified DAO and G72 as putative risk genes for schizophrenia. G72 was a previously unidentified gene shown to overlap with markers within the chromosome 13q34 region associating with schizophrenia. A biochemical analysis showed DAO as a binding partner of the G72 protein product, and the investigators therefore examined single-nucleotide polymorphisms (SNPs) within DAO for association with schizophrenia in their French-Canadian case-control sample. They identified four DAO SNPs, all intronic, known as MDAAO4-7 (Figure 1 ), which showed both association and marginal evidence for epistasis with G72. These and other DAO SNPs were subsequently examined in a number of case-control and familybased studies of schizophrenia, providing the usual mixture of positive [164] [165] [166] [167] [168] and negative 152,169-173 results. In addition, one study reported an association of a DAO SNP with depression and anxiety symptoms in schizophrenia. 174 The data (other than Ohnuma et al. 168 and Jonsson et al. 173 ) were included in three meta-analyses, all of which used the same 'SzGene' database (http:// www.schizophreniaforum.org/res/sczgene), although with differing inclusion criteria. Allen et al. 175 metaanalysed the case-control data frozen at 30 April 2007. A SNP in DAO, rs4623951 (MDAAO-1; Figure 1 ), showed significant (P < 0.026) association across all ethnicities, with a protective effect of the T allele (OR = 0.88, 95% CI: 0.79-0.98); however, using standard 'Venice' epidemiological criteria, 176 it ranked as only 'weak' (category C) evidence, because although the amount and replication of evidence was considered strong (category A), the OR was low. Sun et al. 177 used the database as on 3 August 2007 and also limited their analysis to the case-control data. They adopted a conceptually and statistically different approach-a survey and gene ranking rather than a formal meta-analysis, with a P-value derived from the combined OR method. Of the 75 genes that met a nominal P < 0.05 overall significance, DAO was eighth in the list, with a combined OR of 1.31, P = 1.1 Â 10
À6
. Shi et al. 178 included DAO in their meta-analysis of 12 'top' genes, using the data in SzGene as on 1 March 2008. Unlike the other two meta-analyses, Shi et al. combined case-control and family-based studies (although only one family-based study 152 was actually included) and applied a genewide corrected significance. The same DAO SNP as in the study by Allen et al., 175 rs4623951, showed significant association with schizophrenia (OR = 0.84, 95% CI: 0.75-0.94; P = 0.002), with the result virtually unaffected by exclusion of the family-based study, and with no evidence for publication bias. Three other DAO SNPs (rs2111902, rs3918346 and rs3741775 (namely MDAAO4, MDAAO5 and MDAAO6)) showed no evidence for association with schizophrenia (all P > 0.3).
The three meta-analyses provide a moderate degree of support for an association between DAO and schizophrenia, specifically for rs4623951. However, some studies or SNPs were omitted for various reasons (for example, the manner by which data had been presented in the original study), and hence the meta-analyses did not capture all the available data sets. In addition, neither have haplotype analyses been conducted, nor has a causal variant been identified. Nevertheless, DAO may be considered to be in the category of schizophrenia susceptibility genes for which there are reasonable grounds to defend, and continue to investigate its candidacy.
The mechanism underlying any genetic association of DAO with schizophrenia remains unclear. As the associated SNPs in the DAO gene are non-coding, being either in non-coding regions or synonymous, any pathophysiological functionality is likely exerted through an effect on DAO expression. In turn, the altered DAO expression could affect D-serine or other DAO substrate levels. However, Burnet et al.
11 found no effect of two DAO tag SNPs (rs2070587 in intron 1 and rs3741775 in intron 4) on DAO expression or activity, and Yamada et al.
152 found no effect of the DAO genotype (six of the SNPs studied by Chumakov et al., 8 including rs4623951) on serum D-serine. Thus, there is no evidence to support the proposed molecular basis for the association of DAO with schizophrenia, although these negative studies are not definitive in terms of either SNP coverage or sample size. One study has assessed potential SNP functionality in terms of their impact on cognitive endophenotypes related to schizophrenia, but found no association of three DAO SNPs (MDAAO5-7) with performance on a broad range of cognitive tasks. 179 DAO was originally identified as a candidate gene by virtue of its biochemical and genetic interactions with G72. 8 However, neither interaction has been well replicated. Corvin et al. 167 failed to confirm the multiplicative effect between the same SNPs in DAO and G72, although they did report epistasis between two other SNPs, whereas another study 165 found no epistatic interactions between DAO and G72. Biochemically, the evidence is also conflicting. G72 was originally reported to activate DAO's oxidization of D-serine. 8 Sacchi et al. 20 found that G72 and DAO co-immunoprecipitated from the human cortex; however, G72 decreased rather than increased DAO activity. On the other hand, Kvajo et al. 180 found that DAO and G72 could not be coimmunoprecipitated when expressed in the same cells, nor co-localized to the same subcellular compartments, and that G72 expression did not modulate DAO activity. Moreover, a comprehensive recent study could not identify G72 expression in the human brain, 181 in contrast to an earlier report, 182 casting doubt on the possibility of an interaction between G72 and DAO in vivo. Thus, despite continuing evidence that G72 may itself be a schizophrenia gene 177, 183 and that G72 transgenic mice display a relevant behavioural phenotype, 184 it is not established that G72 activates, or even interacts with, DAO, and suggests that the renaming of G72 as a DAO activator was premature.
DAO expression and activity in schizophrenia
The possibility that DAO may be involved pathophysiologically in schizophrenia is advanced by recent findings that its expression and activity are increased in the disorder. Table 3 summarizes these data, together with those regarding SRR and Asc-1 (ASCT2 has not been measured), as alterations in these might compound or ameliorate DAO changes. In a small study, Kapoor et al. 21 reported elevated DAO mRNA and enzyme activity in the cerebellum, with no change in DAO mRNA in the cerebral cortex. The cortical and cerebellar mRNA findings were replicated in a larger study, 19 and DAO immunoreactivity showed a trend increase in the cerebellum, but could not be quantified in the prefrontal cortex. 19 A third study, in a separate and larger cohort, confirmed elevated cerebellar DAO mRNA and activity in schizophrenia. 11 Increased DAO activity was also found in the parietal cortex, 12 while Bendikov et al. 18 found unchanged DAO protein in the prefrontal cortex and hippocampus. Taken together, these data 
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Increased DAO mRNA in CB (P = 0.004), with trend for DAO IR (P = 0.062). DAO mRNA unchanged in PFC Burnet et al. 18/20 Asc-1 IR reduced in PFC (P = 0.011) and CB (P = 0.028), with Asc1 mRNA unchanged Abbreviations: ACC, anterior cingulate cortex; CB, cerebellum; HC, hippocampus; IR, immunoreactivity; PC, parietal cortex; PFC, prefrontal cortex; PVC, primary visual cortex; STG, superior temporal gyrus. a Mood disorder subjects also studied. b Stated, but data not presented.
Role of DAO in schizophrenia L Verrall et al provide clear evidence of increased cerebellar DAO in schizophrenia, whereas the data in the other regions are more ambiguous, perhaps reflecting the uncertainties regarding the levels, activity and function of DAO in the forebrain (see above). Studies of SRR in schizophrenia are inconsistent (Table 3) , but overall do not suggest that there is a compensatory increased synthesis of D-serine; however, as only the SRR expression and not the enzyme activity has been measured, this conclusion is tentative. Increased cerebellar DAO activity in schizophrenia may be caused by one of several reasons. The fact that DAO mRNA is increased (and correlates with DAO activity) 11 indicates that the mechanism is likely to involve transcriptional regulation. However, as noted, it does not seem to be related to the DAO genotype; 11 in any event, as DAO risk alleles are carried by only a minority of cases and by some control subjects, this could not explain the observed differences between diagnostic groups. G72 mRNA is reportedly increased in schizophrenia, 182 and if it is a DAO activator, then this might be a contributory factor; however, the uncertainties noted above regarding the relationship between G72 and DAO, and regarding the expression of G72 in the brain, make this speculative. Another possibility is antipsychotic medication. One study 19 found a non-significant B10% increase in DAO immunoreactivity in rats administered haloperidol for 2 weeks, and another 12 found higher DAO activity in medicated patients with schizophrenia or bipolar disorder compared with antipsychotic-free cases. However, the latter effect may reflect illness features or severity, not medication, as DAO expression and activity do not correlate with lifetime or recent antipsychotic exposure in patients 11, 12 and DAO activity is unaffected in rats that were administered haloperidol. 11, 12 Taken together, these data imply that elevated DAO expression in schizophrenia is unlikely to be due to antipsychotic medication. Instead, it is tempting to argue that it is part of the glutamatergic pathophysiology of the disorder, downstream of the various genetic and environmental factors and their interactions that appear to converge on NMDAR signalling. However, further research is necessary if this notion is to be replaced by a more specific and falsifiable proposal. One clue may come from the fact that there is a correlation between duration of illness and DAO expression and activity in the hippocampus 18 and in the cerebellum. 11 This might reflect a progression of the aspects of the illness that are being affected (or at least indexed) by DAO. However, no such correlations have been seen in the neocortex. 12, 18 Not only is the cause of increased DAO in schizophrenia unknown, but its implications are also not straightforward. First, because the increase is established only in the cerebellum, a region not usually associated with the core pathophysiology or phenomenology of the disorder. However, there is diverse evidence for cerebellar involvement in schizophrenia, particularly in its cognitive and motor domains. [185] [186] [187] [188] There are also data showing cerebellar modulation of forebrain function, including dopamine release. 189 As such, an increase in DAO activity in schizophrenia may be pathophysiologically significant even if it does prove to be limited to the cerebellum. Second, it is not clear whether D-serine is functional in the cerebellum as levels in the adult cerebellum are very low (Table 2 )-presumably because DAO activity is high. Moreover, exogenous DAO has no effect on cerebellar NMDAR activity, 70 supporting the view that glycine and not D-serine serves as the NMDAR co-agonist in the cerebellum. 68 In this light, it could be argued that increasing cerebellar DAO activity further (as in schizophrenia) will have little or no effect. On the other hand, D-serine may have a spatially limited role within the cerebellum. In particular, the Bergmann glia contain D-serine 68, 69, 190 and, as noted earlier, express abundant DAO. 6, 7, 19, 33, 104 These cells envelop and regulate synaptic inputs to Purkinje cells, [191] [192] [193] and thus D-serine released from the Bergmann glia may modulate Purkinje cell NMDAR 194 and GluRd2 97 signalling, and hence cerebellar output. By the same token, elevated DAO in schizophrenia could indirectly contribute to cerebellar dysfunction. As a final suggestion, increased DAO in schizophrenia, in any brain region, could be pathophysiological through an increased production of hydrogen peroxide, leading to apoptosis, 126, 195, 196 a process proposed to be involved in schizophrenia, although with limited evidence. 197, 198 In total, the increased expression and activity of DAO in schizophrenia supports a role for the enzyme as a pathophysiological factor. Whether this is a major or minor role, and how it relates to any genetic involvement of DAO in the disorder, remains unclear. Constitutive and conditional DAO transgenic mice, as well as further human brain studies, will help clarify these issues.
DAO as a target for the treatment of schizophrenia As noted above, both D-serine and D-alanine show some effectiveness as add-on treatment in schizophrenia, in particular for the amelioration of negative and possibly cognitive symptoms. There are also comparable approaches and data regarding glycine augmentation. 154, 157 As enzymes represent viable drug targets, DAO is receiving attention as a potential alternative therapeutic means to enhance NMDAR function in schizophrenia. 10, 62, [199] [200] [201] [202] [203] [204] The fact that DAO activity seems to be increased in schizophrenia provides another reason to propose that its inhibition might be beneficial. It is also intriguing that the original antipsychotic, chlorpromazine, was shown to be a DAO inhibitor in vitro more than 50 years ago, 2 confirmed recently 205 and also found to apply to risperidone; 206 whether these observations are relevant clinically remains unknown, but they do provide a precedent for the potential therapeutic benefits of selective DAO inhibitors.
To date, there have been no clinical trials of DAO inhibitors in schizophrenia, but several preclinical studies. Although findings remain preliminary, they 202 Several other small molecule DAO inhibitors have been patented, but their behavioural effects have yet to be reported. 62, 204 The ddY/DAO-mice have improved spatial working memory in the Morris water maze 9, 207 and enhanced learning in fear-based tasks, 207 supporting a role for DAO in modulating cognitive processes. Complementing these data, DAO inhibition can correct NMDAR antagonist-induced deficits in prepulse inhibition 10, 201, 203 and possibly in other behaviours (Table 4) . Moreover, SRR genetically modified mice, which have a B90% depletion of D-serine have impaired spatial memory, 208 and reduced pre-pulse inhibition and sociability, 209 indirectly supporting the possibility that restoring D-serine levels may be therapeutic against deficits of this kind in schizophrenia. A pertinent question is whether there are potential advantages to doing so using a DAO inhibitor rather than by D-serine administration. There are two reasons to propose this. First, a DAO inhibitor will also increase levels of D-alanine and its other substrates, which might be beneficial. Second, a DAO inhibitor will avoid the potential for nephrotoxicity which might emerge from the renal oxidation of administered D-serine, [210] [211] [212] [213] [214] as kidney DAO will be inhibited.
However, despite the data summarized in Table 4 and the rationale for DAO inhibitors, there remain substantial hurdles, of which the first two also apply to other strategies to elevate D-serine levels. (1) Part of the case for the use of DAO inhibitors is the evidence that D-serine is reduced in schizophrenia, yet levels of D-serine in the brain (as opposed to the plasma and cerebrospinal fluid) are not decreased 18, 41, 51 and even the reductions in plasma and cerebrospinal fluid have not been replicated in recent studies. 215, 216 (2) If DAO inhibition were markedly to increase brain D-serine, it would not be without risks, because of the potential for oxidative damage 217 and neurotoxicity. 85, 218, 219 It might also lead to NMDAR internalization, limiting its therapeutic value. 220 ( 3) The existing data show that DAO inhibitors can ameliorate some NMDAR antagonist-induced deficits. However, this is not seen across all behaviours, nor is there evidence for an antipsychotic-like profile (Table 4) . Moreover, biochemical and behavioural effects are sometimes seen only when the inhibitor is given in conjunction with systemic D-serine or D-alanine. 201, 203 Although these limitations may reflect the poor brain penetration and modest potency of the drugs tested so far, it may transpire that DAO inhibition alone cannot achieve the desired range and robustness of efficacy, especially as the negative findings by Smith et al. 202 occurred despite a substantial (80%) inhibition of brain and peripheral DAO. (4) Female ddY/DAOmice exhibit increased anxiety, 53 suggesting a possible anxiogenic side effect of DAO inhibition.
These various issues highlight the fact that the complex and poorly understood interplay between DAO, D-serine and NMDAR regulation, noted repeatedly in this review, complicate our understanding of the mechanism(s) by which DAO inhibition might, or might not, prove to be therapeutic. 157, 204 Conclusions and future directions DAO, as the enzyme that degrades the NMDAR coagonist D-serine, has the potential to modulate NMDAR function and to contribute to NMDAR hypofunction in schizophrenia. Both genetic and biochemical data support an involvement of DAO in 
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Normal LMA. Reduction of stereotypy and ataxia induced by MK-801 Maekawa et al. 9 Increased LTP in CA1, and improved spatial learning in the water maze Almond et al. 17 Reduced LMA. PPI unaffected. Reduced responses to PCP, and to a glycine site antagonist Hashimoto et al.
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Marked reduction of methamphetamine-induced stereotypy Labrie et al. 53 Elevated anxiety in females in the open-field and elevated-plus maze Labrie et al. 205 Improved memory for a new target location in the water maze. Improved extinction memory
Selective DAO inhibitors
Adage et al. No acute effects on MK-801-induced deficits in novel object recognition, or on amphetamineinduced LMA or mesolimbic dopamine release Abbreviations: DAO, D-amino acid oxidase; LMA, locomotor activity; LTP, long-term potentization; MK-801, dizocilpine; PCP, phencyclidine; PPI, pre-pulse inhibition of startle.
Role of DAO in schizophrenia L Verrall et al the disorder; however, the processes involved are difficult to interpret. This is due to the many questions left unanswered regarding the neurobiology of DAO and its physiological roles. Notably, there is still much that is unclear as to its localization and activity within the brain, and its spatial and functional relationships with its substrates. In addition, D-serine and thus DAO may have roles other than NMDAR modulation, whereas other DAO substrates, especially D-alanine, may also be relevant to any involvement of DAO in schizophrenia. Similarly, although recent preclinical data hint at potential therapeutic benefits of DAO inhibitors, further extensive study is required to establish their efficacy, tolerability and mechanism.
Finally, we note that many of the issues covered in this review are relevant to other molecules that are being investigated in schizophrenia which are both possible susceptibility genes and drug targets, such as nicotinic a7 receptors, 221 DISC-1, 222 and catechol-Omethyl transferase. 223 For example, to what extent does their candidacy as a risk gene influence therapeutic considerations, and vice versa? When contemplating the gene product as a target, how important is the evidence that there is altered expression or function of the gene in the disease? Group II metabotropic glutamate receptors also come into the category of having diverse yet inconclusive evidence for an aetiopathogenic involvement in schizophrenia, and with a neurobiological and pharmacological rationale to propose them as drug targets. [224] [225] [226] The randomized clinical trial showing that an agonist of these receptors is an effective antipsychotic provides an important precedent, 227 and gives impetus to continue to address these questions with regard to DAO. Equally, the failure yet to replicate this result is testament to the hurdles faced by the field. 
